Guardant Health, INC Form 4 insider transactions

John G. Saia, Chief Legal Officer of Guardant Health, Inc., reported the acquisition and disposal of company stock and restricted stock units on January 1, 2025.

Guardant Health's Chief Information Officer, Kumud Kalia, executed stock transactions involving the vesting of restricted stock units and the sale of shares to cover tax obligations.

Chris Freeman, Chief Commercial Officer of Guardant Health, reports the vesting and subsequent tax withholding of restricted stock units.

Craig Eagle, Chief Medical Officer of Guardant Health, reports the vesting and disposal of restricted stock units to cover tax obligations.

Darya Chudova, Chief Technology Officer of Guardant Health, reports the vesting of restricted stock units and subsequent tax withholding.

Guardant Health's Chief Financial Officer, Michael Bell, executed transactions involving common stock and restricted stock units on January 1, 2025.

AmirAli Talasaz, Co-Chief Executive Officer of Guardant Health, reported transactions involving the acquisition and disposal of company stock and restricted stock units.

Helmy Eltoukhy, Co-Chief Executive Officer of Guardant Health, Inc., reports transactions involving common stock and restricted stock units.

Director Steve Krognes reports the vesting and conversion of restricted stock units into common stock of Guardant Health, Inc.

Tariq Musa, a director at Guardant Health, sold 116 shares of common stock at a price of $34.85 per share on December 18, 2024.

Guardant Health's Chief Legal Officer, John G. Saia, reported the acquisition of 1,020 shares and the disposal of 535 shares to cover tax obligations related to vesting restricted stock units.

Director Myrtle S. Potter of Guardant Health, Inc. reports the vesting of restricted stock units and subsequent disposal of shares.

Guardant Health's Chief Information Officer, Kumud Kalia, reported the vesting of restricted stock units and subsequent tax withholding transactions.

Guardant Health's Chief Commercial Officer, Chris Freeman, reported the acquisition of 1,402 shares and the disposal of 597 shares to cover tax obligations related to vesting restricted stock units.

Craig Eagle, Chief Medical Officer of Guardant Health, reported the acquisition of 1,402 shares and the disposal of 711 shares to cover tax obligations related to vesting restricted stock units.

Guardant Health's Chief Financial Officer, Michael Bell, reported the acquisition and disposal of company stock and restricted stock units on December 15, 2024.

Director Tariq Musa of Guardant Health, Inc. engaged in stock transactions, including the sale of 2,320 shares and the vesting of 250 restricted stock units.

Director Meghan Joyce of Guardant Health acquired 67 shares of common stock through the vesting of restricted stock units.

Meghan V. Joyce, a director at Guardant Health, sold 100 shares of common stock on December 2, 2024.

John G. Saia, Chief Legal Officer of Guardant Health, Inc., reported the acquisition and disposal of company stock and restricted stock units on December 1, 2024.

Guardant Health's Chief Information Officer, Kumud Kalia, reported the acquisition of 710 shares of common stock and the disposal of 360 shares to cover tax obligations related to vesting restricted stock units.

Darya Chudova, Chief Technology Officer of Guardant Health, reported the acquisition and disposal of company stock and restricted stock units on December 1, 2024.

Director Steve Krognes of Guardant Health, Inc. reported the acquisition of 154 shares of common stock through the vesting of restricted stock units.

Guardant Health's Chief Information Officer, Kumud Kalia, sold 7,000 shares of common stock at an average price of $29.246 per share on November 18, 2024.

Director Tariq Musa of Guardant Health acquired 250 shares of common stock and 250 restricted stock units through vesting on November 15, 2024.

Myrtle S. Potter, a director at Guardant Health, acquired 68 shares of common stock through the vesting of restricted stock units.

Meghan V. Joyce, a director at Guardant Health, sold 2,896 shares of common stock at an average price of $29.9017 per share.

Director Ian T. Clark of Guardant Health executed multiple stock transactions, including option exercises and sales, and transferred shares to a family trust.

Guardant Health's Chief Legal Officer, John G. Saia, was granted stock options and restricted stock units on November 8, 2024, as reported in a Form 4 filing.

Terilyn J. Monroe, Chief People Officer at Guardant Health, was granted stock options and restricted stock units on November 8, 2024.